scholarly journals Chronic Recurrent Multifocal Osteomyelitis of the First Metatarsal Bone: A Case Report

2009 ◽  
Vol 17 (1) ◽  
pp. 119-122 ◽  
Author(s):  
CK Chiu ◽  
VA Singh
Keyword(s):  
Case Report ◽  
Symptomatic Relief ◽  
Chronic Recurrent Multifocal Osteomyelitis ◽  
Metatarsal Bone ◽  
First Metatarsal ◽  
History Of ◽  
Multifocal Osteomyelitis ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

We report a case of chronic recurrent multifocal osteomyelitis in a 9-year-old girl. She presented with a 9-month history of gradually worsening pain and swelling in her left foot. Non-steroidal anti-inflammatory drugs were prescribed but the symptoms persisted. She underwent curettage through a small oval corticotomy window on the first metatarsal bone. The pain and swelling improved promptly and she was able to walk without pain 2 weeks later. Curettage enabled rapid symptomatic relief and induced remission, with little risk of complications.

scholarly journals POS1306 TREATMENT STRATEGIES IN CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS (CMRO) OR CHRONIC NON-BACTERIAL OSTEOMYELITIS (CNO): SYSTEMATIC REVIEW AND META-ANALYSIS

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 935.1-935
Author(s):  
R. Dos-Santos ◽  
C. Gomez-Vieites ◽  
D. Fernández Fernández ◽  
I. González Fernández ◽  
A. Souto Vilas ◽  
...  
Keyword(s):  
Treatment Guidelines ◽  
Meta Analysis ◽  
Chronic Recurrent Multifocal Osteomyelitis ◽  
Response Rates ◽  
Complete Response ◽  
Treatment Recommendation ◽  
Remission Rates ◽  
Multifocal Osteomyelitis ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Background:Glucocorticoids (GC), bisphosphonates (BP), non-steroidal anti-inflammatory drugs (NSAID) and classical synthetic or biological disease-modifying antirheumatic drugs (cs/bDMARD) have been employed in the treatment of chronic recurrent multifocal osteomyelitis (CRMO) or chronic non-bacterial osteomyelitis (CNO).1, 2 This one is a rare bone childhood illness and none treatment guidelines have been carried out till present.3Objectives:To asses which treatment schedule employed in CRMO had the best response rates and try to expose a treatment recommendation.Methods:A systematic literature review was made using Medline, Embase, Cochrane library and the Web of Science databases. The search strategy focused on synonyms of CRMO. A prevalence meta-analysis was performed to evaluate each treatment response. Stata 15.1 was used to perform statistical analysis.Results:The search identified 1883 articles, of which 43 were finally selected. Complete response rate reached with NSAIDs was acceptable [50% (CI95% 40-60)]. Lower response rates were reached by GC treatment [44% (CI95% 25-63)] or csDMARD [38% (CI95% 28-48)]. The best complete response rates were reached by bDMARD and BP treatments [69% (CI95% 56-82) and 73% (CI95% 62-84), respectively].Conclusion:This review and meta-analysis supports, taking into account its remission rates and its risk-benefit profile, NSAIDs as potential first-line agents in CRMO treatment. bDMARD and BP have reached the higher remission rates, turning into helpful treatment alternatives. There is not any treatment guidelines driving CRMO patients, but this analysis could help to select a suitable agent for each patient. Decision-making should be individualized.References:[1]Wipff J, Costantino F, Lemelle I, et al. A large national cohort of French patients with chronic recurrent multifocal osteitis. Arthritis & Rheumatol. 2014;67(4):1128-1137.[2]Zhao Y, Wu E Y, Oliver M S, et al. Consensus treatment plans for chronic nonbacterial osteomielitis refractory to nonsteroideal anti-inflammatory drugs and/or with active spinal lesions. Arthritis Care Res. 2018;70(8):1228-1237.[3]Menashe SJ, Aboughalia H, Zhao Y, et al. The many faces of pediatric chronic recurrent multifocal osteomyelitis (CRMO): a practical location- and case-based approach to differenciate CRMO from its mimics. J Magn Reson Imaging. 2020;e27299.Disclosure of Interests:None declared

scholarly journals Natural History of Paclitaxel-associated Acute Pain Syndrome: A Case Report of Rare Side Effect of Paclitaxel

2021 ◽  
Vol 9 (C) ◽  
pp. 239-242
Author(s):  
Siti Salima ◽  
Ali Budi Harsono ◽  
Aisyah Aisyah ◽  
Kemala Mantilidewi
Keyword(s):  
Case Report ◽  
Side Effects ◽  
Acute Pain ◽  
Side Effect ◽  
Supportive Therapy ◽  
Pain Syndrome ◽  
Rare Side Effect ◽  
History Of ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

BACKGROUND: One of the harshest side effects following anticancer agent treatments is chemotherapy-induced neuropathic pain. After surgical staging, chemotherapy combination of paclitaxel carboplatin could be a choice of therapy for Stage II or more advanced stage of ovarian cancer. Different side effects may appear after the application of paclitaxel. CASE REPORT: Here, we show an uncommon case of paclitaxel-acute pain syndrome (P-APS), and how we deal with such cases according to our experiences. One uncommon side effect is P-APS, which can be treated effectively with the administration of non-steroidal anti-inflammatory drugs, corticosteroid, and supportive therapy. CONCLUSION: One uncommon side effect of Paclitaxel induced neuropathic can be treated effectively with the administration of non-steroidal anti inflammatory drugs, corticosteroid, and supportive therapy.

scholarly journals Idiopathic small bowel diaphragm disease: a case report

2020 ◽  
Vol 2020 (10) ◽  
Author(s):  
Omar Marghich ◽  
Alexandre Maubert ◽  
Efoé-Ga Yawod Olivier Amouzou ◽  
Louis Denimal ◽  
Emmanuel Benizri ◽  
...  
Keyword(s):  
Case Report ◽  
Small Bowel ◽  
Rare Condition ◽  
Diaphragm Disease ◽  
History Of ◽  
Inflammatory Drugs ◽  
Nsaid Usage ◽  
Anti Inflammatory

Abstract Small bowel diaphragm disease is a rare condition usually associated with the prolonged use of non-steroidal anti-inflammatory drugs (NSAID) and that can be mistaken and treated as other pathologies. We describe a case of a 64-year-old man with a prolonged course of pain and subacute bowel obstructions, without any history of NSAID usage, found to have a multiple diaphragmatic stricture in the small bowel.

scholarly journals Beyond the guidelines management of juvenile idiopathic arthritis: a case report of a girl with polyarticular disease refractory to multiple treatment options and Leri Weill syndrome

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Vana Vukić ◽  
Ana Smajo ◽  
Mandica Vidović ◽  
Rudolf Vukojević ◽  
Miroslav Harjaček ◽  
...  
Keyword(s):  
Juvenile Idiopathic Arthritis ◽  
Case Report ◽  
Treatment Options ◽  
Janus Kinase ◽  
Musculoskeletal Symptoms ◽  
Multiple Treatment ◽  
Number Of Patients ◽  
Systemic Glucocorticoids ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Abstract Background The last two decades brought new treatment options and high quality guidelines into the paediatric rheumatologic practice. Nevertheless, a number of patients still present a diagnostic and therapeutic challenge due to combination of vague symptoms and unresponsiveness to available treatment modalities. Case presentation We report a case of sixteen years old girl suffering from polyarticular type of juvenile idiopathic arthritis refractory to multiple treatment options. She first presented at the age of 4 with swelling and contractures of both knees. Her symptoms were initially unresponsive to nonsteroidal anti-inflammatory drugs and progressed despite treatment with intraarticular and systemic glucocorticoids and methotrexate. Throughout the years, she received several biologics together with continuous administration of nonsteroidal anti-inflammatory drugs and disease modifying anti-rheumatic drugs as well as intraarticular and systemic glucocorticoids in disease flares. However, none of this options  provided a permanent remission, so various other modalities, as well as other possible diagnoses were constantly being considered. Eventually she became dependent on a daily dose of systemic glucocorticoids. In 2018, the treatment with Janus kinase inhibitor tofacitinib was initiated, which led to gradual amelioration of musculoskeletal symptoms, improvement of inflammatory markers and overall well-being, as well as to the weaning of systemic glucocorticoids. As the swelling of the wrists subsided for the first time in many years, Madelung’s deformity was noticed, first clinically, and later radiographically as well. Genetic analysis revealed short-stature homeobox gene deficiency and confirmed the diagnosis of Leri Weill syndrome. Conclusions This case report emphasizes the need for reporting refractory, complicated cases from everyday clinical practice in order to build-up the overall knowledge and share experience which is complementary to available guidelines. Individual reports of difficult to treat cases, especially when additional diagnoses are involved, can be helpful for physicians treating patients with common rheumatological diseases such as juvenile idiopathic arthritis.

scholarly journals Myositis as a Disease Manifestation of Chronic Recurrent Multifocal Osteomyelitis: A case report.

2021 ◽  
Author(s):  
Vinicius Verlangieri Soubihe ◽  
Diego de Paula Ferreira Nunes ◽  
Raíssa Dudienas Domingues Pereira ◽  
Caio Rustichelli Cardoso ◽  
Thaís Ferrarini Tavares ◽  
...  
Keyword(s):  
Case Report ◽  
Chronic Recurrent Multifocal Osteomyelitis ◽  
Disease Manifestation ◽  
Multifocal Osteomyelitis

scholarly journals Acute Myopericarditis in a Pediatric Patient after First Dose of Pfizer BioNTech COVID - 19 Vaccination: First Case Report in the Kingdom of Bahrain

2021 ◽  
Vol 33 (4) ◽  
pp. 29-32
Author(s):  
Ghada Al Qassim ◽  
Vimalarani Arulselvam ◽  
Suad R Al Amer ◽  
Salah Al Ghanem ◽  
Neale Nicola Kalis
Keyword(s):  
Case Report ◽  
Adverse Events ◽  
Pediatric Patient ◽  
Task Force ◽  
Limited Data ◽  
First Case ◽  
National Task ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Coronavirus disease 201 9 (COVID - 1 9 ) vaccination for children over 12 years of age began on May 2021 in the kingdom of Bahrain. Very limited data is available regarding the adverse events related to COVID -19 vaccination in children. This is a case report of a 12-year-old previously healthy boy with acute myopericarditis who presented on day 5 after the first dose of Pfizer COVID - 19 vaccination. Other causes of acute myopericarditis were ruled out. He was treated with non - steroidal anti-inflammatory drugs and recovered fully. This case of vaccine-induced myocarditis was reported to the national task force of Bahrain for combating COVID - 19.

scholarly journals Gynecomastia in a Patient Taking Meloxicam—A Case Report

2020 ◽  
Vol 11 ◽  
pp. 215013272095262
Author(s):  
Steven L. Rosas ◽  
Mark E. Deyo-Svendsen ◽  
Rachel Z. Oldfather ◽  
Michael R. Phillips ◽  
T. Andrew Israel ◽  
...  
Keyword(s):  
Case Report ◽  
Male Breast ◽  
Medical Illness ◽  
Glandular Tissue ◽  
Adult Men ◽  
Antiretroviral Medications ◽  
Causative Agents ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Gynecomastia is benign enlargement of glandular tissue in the male breast. It occurs due to an imbalance of estrogen and testosterone. It may be unilateral or bilateral. Physiologic gynecomastia commonly occurs in infants and during puberty and is self-limited. Gynecomastia may affect up to 50% of adult men over age 50 years old and can be related to underlying medical illness or caused by certain medications. Known causative agents include anti-androgenic and estrogenic drugs. Probable agents include alcohol and anti-ulcer, psychoactive, and antiretroviral medications. Non-steroidal anti-inflammatory drugs (NSAIDs) are not commonly associated with the development of gynecomastia. This case presents an instance in which the NSAID, meloxicam, was the only identified variable in a patient who developed unilateral gynecomastia. His breast tenderness and abnormal exam resolved spontaneously within 4 weeks of cessation of meloxicam therapy.

Sign in / Sign up

Export Citation Format

Share Document